Foghorn Therapeutics Stock Plummets as Eli Lilly Partnership Ends on Cancer Drug
Foghorn Therapeutics (FHTX) shares dropped nearly 45% in pre-market trading after announcing it would discontinue the development of its experimental cancer drug FHD-909, a move made under its partnership with Eli Lilly (LLY).